Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma.
Akinori Minato; Tomohisa Takaba; Yoshihiro Sugita; Yuya Kaneko; Ryota Hongyo; Toshinobu Tanaka; Taro Bando; Takaomi Sugi; Yui Mizushima; Takuo Matsukawa; Kazumasa Jojima; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Eiji Kashiwagi
Japanese journal of clinical oncology, Jul. 2025, Reviewed, No invitation

Pioglitazone Suppresses Urothelial Tumorigenesis In Vitro: A Potential Chemopreventive Agent.
Nguyen Thu Quynh; Yujiro Nagata; Takuo Matsukawa; Eiji Kashiwagi; Naohiro Fujimoto
Cancer genomics & proteomics, 2025, Reviewed, No invitation

Recent advances in understanding the role of sex hormone receptors in urothelial cancer.
Mohammad Amin Elahi Najafi; Takuo Matsukawa; Hiroshi Miyamoto
Oncology research, 2025, Reviewed, No invitation

Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.
Yujiro Nagata; Takaomi Sugi; Sohei Yamamura; Yoshihiro Sugita; Yui Mizushima; Takuo Matsukawa; Tomohisa Takaba; Kazumasa Jojima; Katsuyoshi Higashijima; Masahiro Matsumoto; Akinori Minato; Ikko Tomisaki; Eiji Kashiwagi; Naohiro Fujimoto
In vivo (Athens, Greece), 2025, Reviewed, No invitation

Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience.
Akinori Minato; Yui Mizushima; Yoshihiro Sugita; Tomohisa Takaba; Takuo Matsukawa; Kazumasa Jojima; Rieko Kimuro; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Eiji Kashiwagi; Naohiro Fujimoto
In vivo (Athens, Greece), 2025, Reviewed, No invitation

Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression.
Yuki Teramoto; Mohammad Amin Elahi Najafi; Takuo Matsukawa; Adhya Sharma; Takuro Goto; Hiroshi Miyamoto
International journal of molecular sciences, Jul. 2024

Mineralocorticoid receptor signaling inhibits bladder cancer progression.
Yujiro Nagata; Takuro Goto; Yuki Teramoto; Takuo Matsukawa; Naohiro Fujimoto; Hiroshi Miyamoto
American journal of cancer research, 2024

PGC1α as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers.
Yuki Teramoto; Zhiming Yang; Takuo Matsukawa; Mohammad Amin Elahi Najafi; Takuro Goto; Hiroshi Miyamoto
American journal of cancer research, 2024

GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer.
Tomoyuki Tatenuma; Takuo Matsukawa; Takuro Goto; Guiyang Jiang; Adhya Sharma; Mohammad Amin Elahi Najafi; Yuki Teramoto; Hiroshi Miyamoto
Cancer genomics & proteomics, 2024

Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Yujiro Nagata; Kazumasa Jojima; Takuo Matsukawa; Ikko Tomisaki; Naohiro Fujimoto
Anticancer research, Oct. 2023

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Akinori Minato; Rieko Kimuro; Daichi Ohno; Kentarou Tanigawa; Keisuke Kuretake; Takuo Matsukawa; Tomohisa Takaba; Kazumasa Jojima; Mirii Harada; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Kenichi Harada; Naohiro Fujimoto; Hiroshi Miyamoto
Anticancer research, Sep. 2023

ANGPTL8 links inflammation and poor differentiation, which are characteristics of malignant renal cell carcinoma.
Takuo Matsukawa; Tomomitsu Doi; Kunie Obayashi; Kazuhiro Sumida; Naohiro Fujimoto; Motoyoshi Endo
Cancer science, Apr. 2023

Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Yujiro Nagata; Takuo Matsukawa; Ikko Tomisaki; Naohiro Fujimoto
Anticancer research, Jan. 2023

[IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER].
Akinori Minato; Ikko Tomisaki; Rieko Kimuro; Katsuyoshi Higashijima; Mirii Harada; Kazumasa Jojima; Takuro Sakamoto; Tomohisa Takaba; Daichi Ohno; Keisuke Kuretake; Kentarou Tanigawa; Takuo Matsukawa; Kenichi Harada; Naohiro Fujimoto
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2023

Protective role of mineralocorticoid receptor signaling in urothelial tumorigenesis.
Yujiro Nagata; Takuo Matsukawa; Takuro Goto; Yuki Teramoto; Guiyang Jiang; Naohiro Fujimoto; Hiroshi Miyamoto
American journal of cancer research, 2023

Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
Yujiro Nagata; Takuo Matsukawa; Ikko Tomisaki; Naohiro Fujimoto
Anticancer research, Feb. 2022

Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells.
Satoshi Endo; Mina Kawai; Manami Hoshi; Jin Segawa; Mei Fujita; Takuo Matsukawa; Naohiro Fujimoto; Toshiyuki Matsunaga; Akira Ikari
Journal of biochemistry, Sep. 2021

Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer.
Naohiro Fujimoto; Masaki Shiota; Takuo Matsukawa; Akinori Minato; Ikko Tomisaki; Rei Ohnishi; Masatoshi Eto
In vivo (Athens, Greece), 2021

Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Satoshi Endo; Hiroaki Oguri; Jin Segawa; Mina Kawai; Dawei Hu; Shuang Xia; Takuya Okada; Katsumasa Irie; Shinya Fujii; Hiroaki Gouda; Kazuhiro Iguchi; Takuo Matsukawa; Naohiro Fujimoto; Toshiyuki Nakayama; Naoki Toyooka; Toshiyuki Matsunaga; Akira Ikari
Journal of medicinal chemistry, Sep. 2020

非典型的な主訴で来院した梅毒の2例
呉竹景介、舟越恵太、野間悠太朗、谷川堅太郎、大野大地、松川卓生、高場智久、城嶋和真、原田みりい、木室里依子、東島克佳、永田祐二郎、湊 晶規、富崎一向、原田健一、藤本直浩、岡田悦子
日本性感染症学会誌, Sep. 2023, Reviewed, No invitation

非典型的な主訴で来院した梅毒の2例
呉竹 景介, 舟越 恵太, 野間 悠太朗, 谷川 堅太郎, 大野 大地, 松川 卓生, 高場 智久, 城嶋 和真, 原田 みりい, 木室 里依子, 東島 克佳, 永田 祐二郎, 湊 晶規, 富崎 一向, 原田 健一, 藤本 直浩, 岡田 悦子
日本性感染症学会誌, Mar. 2024, Null, Null

非典型的な主訴で来院した梅毒の2例
呉竹 景介, 舟越 恵太, 野間 悠太朗, 谷川 堅太郎, 大野 大地, 松川 卓生, 高場 智久, 城嶋 和真, 原田 みりい, 木室 里依子, 東島 克佳, 永田 祐二郎, 湊 晶規, 富崎 一向, 原田 健一, 藤本 直浩, 岡田 悦子
日本性感染症学会誌, Mar. 2024, Reviewed, No invitation

局所進行膀胱癌に対する膀胱全摘除術後補助化学療法の有効性
湊 晶規, 富崎 一向, 木室 里依子, 東島 克佳, 原田 みりい, 城嶋 和真, 坂本 卓郎, 高場 智久, 大野 大地, 呉竹 景介, 谷川 堅太郎, 松川 卓生, 原田 健一, 藤本 直浩
日本泌尿器科学会雑誌, Oct. 2023, Reviewed, No invitation

PGC1α as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers.
Teramoto Yuki, Yang Zhiming, Matsukawa Takuo, Najafi Mohammad Amin Elahi, Goto Takuro, Miyamoto Hiroshi
American journal of cancer research, 2024, Reviewed, No invitation

Mineralocorticoid receptor signaling inhibits bladder cancer progression.
Nagata Yujiro, Goto Takuro, Teramoto Yuki, Matsukawa Takuo, Fujimoto Naohiro, Miyamoto Hiroshi
American journal of cancer research, Feb. 2024, Reviewed, No invitation

Protective role of mineralocorticoid receptor signaling in urothelial tumorigenesis.
Nagata Yujiro, Matsukawa Takuo, Goto Takuro, Teramoto Yuki, Jiang Guiyang, Fujimoto Naohiro, Miyamoto Hiroshi
American journal of cancer research, Feb. 2023, Reviewed, No invitation

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Reviewed, No invitation

Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Nagata Yujiro, Jojima Kazumasa, Matsukawa Takuo, Tomisaki Ikko, Fujimoto Naohiro
Anticancer research, Oct. 2023, Reviewed, No invitation

Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Nagata Yujiro, Matsukawa Takuo, Tomisaki Ikko, Fujimoto Naohiro
Anticancer research, Jan. 2023, Reviewed, No invitation

Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
Nagata Yujiro, Matsukawa Takuo, Tomisaki Ikko, Fujimoto Naohiro
Anticancer research, Feb. 2022, Reviewed, No invitation

GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer.
Tatenuma Tomoyuki, Matsukawa Takuo, Goto Takuro, Jiang Guiyang, Sharma Adhya, Najafi Mohammad Amin Elahi, Teramoto Yuki, Miyamoto Hiroshi
Cancer genomics & proteomics, 2024, Reviewed, No invitation

ANGPTL8 links inflammation and poor differentiation, which are characteristics of malignant renal cell carcinoma.
Matsukawa Takuo, Doi Tomomitsu, Obayashi Kunie, Sumida Kazuhiro, Fujimoto Naohiro, Endo Motoyoshi
Cancer science, Apr. 2023, Reviewed, No invitation
Lead

Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression.
Teramoto Yuki, Elahi Najafi Mohammad Amin, Matsukawa Takuo, Sharma Adhya, Goto Takuro, Miyamoto Hiroshi
International journal of molecular sciences, Jul. 2024, Reviewed, No invitation

Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma.
Minato Akinori, Takaba Tomohisa, Sugita Yoshihiro, Kaneko Yuya, Hongyo Ryota, Tanaka Toshinobu, Bando Taro, Sugi Takaomi, Mizushima Yui, Matsukawa Takuo, Jojima Kazumasa, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Kashiwagi Eiji
Japanese journal of clinical oncology, Mar. 2025, Reviewed, No invitation

Targeting Nrf2-antioxidant signaling reverses acquired cabazitaxel resistance in prostate cancer cells.
Endo Satoshi, Kawai Mina, Hoshi Manami, Segawa Jin, Fujita Mei, Matsukawa Takuo, Fujimoto Naohiro, Matsunaga Toshiyuki, Ikari Akira
Journal of biochemistry, Mar. 2021, Reviewed, Null

Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Endo Satoshi, Oguri Hiroaki, Segawa Jin, Kawai Mina, Hu Dawei, Xia Shuang, Okada Takuya, Irie Katsumasa, Fujii Shinya, Gouda Hiroaki, Iguchi Kazuhiro, Matsukawa Takuo, Fujimoto Naohiro, Nakayama Toshiyuki, Toyooka Naoki, Matsunaga Toshiyuki, Ikari Akira
Journal of medicinal chemistry, Sep. 2020, Reviewed, No invitation

[IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER].
Minato Akinori, Tomisaki Ikko, Kimuro Rieko, Higashijima Katsuyoshi, Harada Mirii, Jojima Kazumasa, Sakamoto Takuro, Takaba Tomohisa, Ohno Daichi, Kuretake Keisuke, Tanigawa Kentarou, Matsukawa Takuo, Harada Kenichi, Fujimoto Naohiro
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2023, Reviewed, No invitation

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Null, Null

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Null, Null

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Null, Null

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Null, Null

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Null, Null

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Null, Null

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Null, Null

Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Nagata Yujiro, Jojima Kazumasa, Matsukawa Takuo, Tomisaki Ikko, Fujimoto Naohiro
Anticancer research, Oct. 2023, Null, Null

Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Nagata Yujiro, Matsukawa Takuo, Tomisaki Ikko, Fujimoto Naohiro
Anticancer research, Jan. 2023, Null, Null

ANGPTL8 links inflammation and poor differentiation, which are characteristics of malignant renal cell carcinoma.
Matsukawa Takuo, Doi Tomomitsu, Obayashi Kunie, Sumida Kazuhiro, Fujimoto Naohiro, Endo Motoyoshi
Cancer science, Apr. 2023, Null, Null

Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer.
Fujimoto Naohiro, Shiota Masaki, Matsukawa Takuo, Minato Akinori, Tomisaki Ikko, Ohnishi Rei, Eto Masatoshi
In vivo (Athens, Greece), Null, Null

[IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER].
Minato Akinori, Tomisaki Ikko, Kimuro Rieko, Higashijima Katsuyoshi, Harada Mirii, Jojima Kazumasa, Sakamoto Takuro, Takaba Tomohisa, Ohno Daichi, Kuretake Keisuke, Tanigawa Kentarou, Matsukawa Takuo, Harada Kenichi, Fujimoto Naohiro
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2023, Null, Null

[IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER].
Minato Akinori, Tomisaki Ikko, Kimuro Rieko, Higashijima Katsuyoshi, Harada Mirii, Jojima Kazumasa, Sakamoto Takuro, Takaba Tomohisa, Ohno Daichi, Kuretake Keisuke, Tanigawa Kentarou, Matsukawa Takuo, Harada Kenichi, Fujimoto Naohiro
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2023, Null, Null